V.М. Kovalenko, Т.V. Talaeva, A.S. Kozliuk, V.V. Bratus. The influence of the prolonged systemic enzyme therapy on cardiovascular risk in patients with osteoarthritis

The aim – to determine the influence of the systemic enzyme therapy on cardiovascular risk level, its relation to the intensity of systemic inflammation and traditional factors of atherogenesis.

Material and methods. The dynamics of the main cardio-vascular risk indexes in patients with osteoarthritis was investigated during 6 months on standard treatment (the control group) and in patients receiving the systemic enzyme therapy drug (the group of treatment).

Results. In patients of the control group, we noted the progressive increase of inflammation and oxidative stress indices, as well as further activation of angiotensin-converting enzyme. These changes were accompanied by proatherogenic changes of the lipid and glucose metabolism, atherogenic and immunogenic modification of the lipoprotein spectrum. In parallel generalized structural and functional remodeling of the arterial vascular wall and endothelial dysfunction was noted. Systemic enzyme therapy sharply inhibited systemic inflammation and oxidative stress in conjunction with restoration of the antioxidant plasma potential. It improved lipid spectrum, decreased hyperglycemia and lowered plasma HbA1c level. Metabolic parameters in patients with low residual inflammation were close to their normal value.

Conclusions. Apart from antiinflammatory action, systemic enzyme therapy in patients with osteoarthritis promotes decrease of cardiovascular risk factors, partially restores the structural and functional properties of the arterial vessels.

Full article